Nothing Special   »   [go: up one dir, main page]

CA3174236A1 - Proteines de fusion d'ace2 et leurs utilisations - Google Patents

Proteines de fusion d'ace2 et leurs utilisations Download PDF

Info

Publication number
CA3174236A1
CA3174236A1 CA3174236A CA3174236A CA3174236A1 CA 3174236 A1 CA3174236 A1 CA 3174236A1 CA 3174236 A CA3174236 A CA 3174236A CA 3174236 A CA3174236 A CA 3174236A CA 3174236 A1 CA3174236 A1 CA 3174236A1
Authority
CA
Canada
Prior art keywords
seq
ace2
human
amino acid
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3174236A
Other languages
English (en)
Inventor
Alwin REITER
Carsten Brockmeyer
Florian WOLSCHIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Formycon AG
Original Assignee
Formycon AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Formycon AG filed Critical Formycon AG
Publication of CA3174236A1 publication Critical patent/CA3174236A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)

Abstract

La présente invention concerne des protéines de fusion d'ACE2 avec IgG Fc et l'utilisation médicale de ces protéines de fusion, en particulier dans la prévention ou le traitement d'infections par des coronavirus tels que le SARS-CoV-2.
CA3174236A 2020-05-22 2021-05-21 Proteines de fusion d'ace2 et leurs utilisations Pending CA3174236A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP20176139.2 2020-05-22
EP20176139 2020-05-22
EP20204774 2020-10-29
EP20204774.2 2020-10-29
EP20210297.6 2020-11-27
EP20210297 2020-11-27
EP21164684 2021-03-24
EP21164684.9 2021-03-24
EP21170519 2021-04-26
EP21170519.9 2021-04-26
PCT/EP2021/063692 WO2021234160A2 (fr) 2020-05-22 2021-05-21 Protéines de fusion d'ace2 et leurs utilisations

Publications (1)

Publication Number Publication Date
CA3174236A1 true CA3174236A1 (fr) 2021-11-25

Family

ID=76138076

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3174236A Pending CA3174236A1 (fr) 2020-05-22 2021-05-21 Proteines de fusion d'ace2 et leurs utilisations

Country Status (8)

Country Link
US (1) US20210363512A1 (fr)
EP (1) EP4139002A2 (fr)
JP (1) JP2023526540A (fr)
KR (1) KR20230015365A (fr)
CN (1) CN115803091A (fr)
AU (1) AU2021275499A1 (fr)
CA (1) CA3174236A1 (fr)
WO (1) WO2021234160A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023534421A (ja) * 2020-07-06 2023-08-09 アヴィルマックス インコーポレイテッド 触媒反応が不活性化されたアンジオテンシン変換酵素２（ａｃｅ２）変異型とその利用
MX2023009921A (es) 2021-03-03 2023-09-05 Formycon Ag Formulaciones de proteinas de fusion ace2-fc.
WO2023006935A2 (fr) 2021-07-30 2023-02-02 Formycon Ag Protéines de fusion ace2 et leurs utilisations
WO2023094571A1 (fr) * 2021-11-25 2023-06-01 Formycon Ag Stabilisation de protéines de fusion ace2
EP4331571A1 (fr) 2022-09-02 2024-03-06 Formycon AG Formulations de protéines de fusion ace2-igm
EP4386084A1 (fr) 2022-12-14 2024-06-19 Formycon AG Protéines de fusion ace2 améliorées
DE102023118690A1 (de) * 2023-07-14 2025-01-16 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer Infektion und/oder Infektionskrankheit und/oder einer Folgeerkrankung davon

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
ATE240395T1 (de) 1994-03-29 2003-05-15 Celltech Therapeutics Ltd Antikörper gegen e-selektin
MX353234B (es) 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
CA2431600C (fr) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules a demi-vies longues, compositions et utilisations de celles-ci
WO2004035752A2 (fr) 2002-10-15 2004-04-29 Protein Design Labs, Inc. Modification d'affinites de liaison pour fcrn ou de demi-vies seriques d'anticorps par mutagenese
US20050282154A1 (en) 2003-10-06 2005-12-22 The Brigham And Women's Hospital, Inc. Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus
DK2325207T3 (en) 2004-11-12 2017-06-06 Xencor Inc Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP1723962A1 (fr) 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Utilisation des inhibiteurs du système de rénine-angiotensine pour le traitement des lesions poumonaires.
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
ES2675730T3 (es) 2008-06-04 2018-07-12 Macrogenics, Inc. Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos
PL2506871T3 (pl) 2009-11-30 2017-03-31 Janssen Biotech, Inc Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi
KR101818274B1 (ko) 2010-05-27 2018-01-12 머크 샤프 앤드 돔 코포레이션 개선된 특성을 갖는 항체의 제조 방법
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
KR20150008082A (ko) 2012-04-27 2015-01-21 바이오아트라, 엘엘씨 수정된 항체 영역 및 그의 용도
CA3117212A1 (fr) * 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Proteines heterodimeres fusionnees a un fragment fc
MX2022010118A (es) * 2020-02-19 2022-09-05 United Biomedical Inc Peptidos y proteinas de dise?o para la deteccion, la prevencion y el tratamiento de la enfermedad por coronavirus de 2019 (covid-19).
WO2021170113A1 (fr) * 2020-02-29 2021-09-02 南京金斯瑞生物科技有限公司 Méthode de traitement de coronavirus à l'aide d'une protéine de fusion ace-2-fc
WO2021205183A1 (fr) * 2020-04-09 2021-10-14 Autolus Limited Polypeptide
WO2021216547A1 (fr) * 2020-04-20 2021-10-28 Sorrento Therapeutics, Inc. Administration pulmonaire de polypeptides ace2
MX2023009921A (es) * 2021-03-03 2023-09-05 Formycon Ag Formulaciones de proteinas de fusion ace2-fc.

Also Published As

Publication number Publication date
KR20230015365A (ko) 2023-01-31
AU2021275499A1 (en) 2022-11-24
EP4139002A2 (fr) 2023-03-01
WO2021234160A2 (fr) 2021-11-25
US20210363512A1 (en) 2021-11-25
WO2021234160A3 (fr) 2022-01-13
CN115803091A (zh) 2023-03-14
JP2023526540A (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
US20210363512A1 (en) ACE2 fusion proteins and uses thereof
US20240018499A1 (en) ACE2 Fusion Proteins and Uses Thereof
WO2018028635A1 (fr) Anticorps monoclonal humanisé contre le virus zika et ses applications
US20240139296A1 (en) Formulations of ace2 fc fusion proteins
US20250009854A1 (en) Antiviral Agent Comprising a Cellular Entry Receptor and Fc Region Component
JP2022501319A (ja) 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用
Svilenov et al. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein
WO2023094571A1 (fr) Stabilisation de protéines de fusion ace2
WO2014115893A1 (fr) Anticorps humain spécifique au virus métapneumovirus humain, ou fragment de liaison d'antigène de celui-ci
US10081671B2 (en) Human monoclonal antibody specific for the F protein of respiratory syncytial virus (RSV)
EP4377452A2 (fr) Protéines de fusion ace2 et leurs utilisations
CN112898426A (zh) 人源化4-1bb单克隆抗体及其药物组合物
CN116848242A (zh) Ace2融合蛋白及其用途
US20230312684A1 (en) Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
US20250027067A1 (en) Improved ace2 fusion proteins
EP4386084A1 (fr) Protéines de fusion ace2 améliorées
US20240209065A1 (en) Secretory iga antibodies against covid infection
WO2023108040A2 (fr) Protéines de fusion ace2-fc et procédés d'utilisation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929

EEER Examination request

Effective date: 20220929